Prime Capital Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.49M | Sell |
25,774
-129
| -0.5% | -$7.41K | 0.01% | 437 |
|
|
2026
Q1 | $1.57M | Buy |
25,903
+817
| +3% | +$47.6K | 0.02% | 401 |
|
|
2025
Q4 | $1.35M | Sell |
25,086
-1,575
| -6% | -$75.8K | 0.02% | 430 |
|
|
2025
Q3 | $1.2M | Sell |
26,661
-1,111
| -4% | -$51.9K | 0.02% | 443 |
|
|
2025
Q2 | $1.29M | Sell |
27,772
-12,306
| -31% | -$604K | 0.02% | 420 |
|
|
2025
Q1 | $2.44M | Buy |
40,078
+7,481
| +23% | +$436K | 0.03% | 330 |
|
|
2024
Q4 | $1.84M | Buy |
32,597
+1,429
| +5% | +$79.8K | 0.03% | 319 |
|
|
2024
Q3 | $1.61M | Sell |
31,168
-1,991
| -6% | -$93.4K | 0.02% | 349 |
|
|
2024
Q2 | $1.38M | Sell |
33,159
-12,949
| -28% | -$579K | 0.02% | 374 |
|
|
2024
Q1 | $2.5M | Sell |
46,108
-5,623
| -11% | -$286K | 0.03% | 307 |
|
|
2023
Q4 | $2.65M | Sell |
51,731
-1,311
| -2% | -$68.8K | 0.04% | 291 |
|
|
2023
Q3 | $3.08M | Sell |
53,042
-3,244
| -6% | -$199K | 0.06% | 210 |
|
|
2023
Q2 | $3.6M | Buy |
56,286
+7,841
| +16% | +$526K | 0.07% | 198 |
|
|
2023
Q1 | $3.36M | Buy |
48,445
+32,194
| +198% | +$2.27M | 0.14% | 129 |
|
|
2022
Q4 | $1.17M | Buy |
16,251
+4,335
| +36% | +$327K | 0.04% | 226 |
|
|
2022
Q3 | $847K | Buy |
11,916
+3,716
| +45% | +$270K | 0.05% | 188 |
|
|
2022
Q2 | $631K | Buy |
+8,200
| New | +$625K | 0.04% | 205 |
|
|
2021
Q3 | – | Sell |
-3,545
| Closed | -$237K | – | 305 |
|
|
2021
Q2 | $237K | Buy |
3,545
+1,132
| +47% | +$73.8K | 0.01% | 336 |
|
|
2021
Q1 | $152K | Sell |
2,413
-126
| -5% | -$7.84K | 0.01% | 262 |
|
|
2020
Q4 | $157K | Sell |
2,539
-45,144
| -95% | -$2.78M | 0.01% | 247 |
|
|
2020
Q3 | $2.88M | Buy |
47,683
+15,941
| +50% | +$959K | 0.24% | 85 |
|
|
2020
Q2 | $1.87M | Sell |
31,742
-19,671
| -38% | -$1.18M | 0.17% | 106 |
|
|
2020
Q1 | $2.87M | Buy |
51,413
+18,823
| +58% | +$1.15M | 0.34% | 58 |
|
|
2019
Q4 | $2.09M | Buy |
32,590
+31,873
| +4,445% | +$1.83M | 0.24% | 96 |
|
|
2019
Q3 | $36K | Sell |
717
-93,393
| -99% | -$4.39M | 0.01% | 334 |
|
|
2019
Q2 | $4.27M | Buy |
94,110
+31,364
| +50% | +$1.46M | 0.78% | 35 |
|
|
2019
Q1 | $2.99M | Buy |
62,746
+62,423
| +19,326% | +$3.11M | 0.87% | 33 |
|
|
2018
Q4 | $17K | Buy |
323
+183
| +131% | +$9.83K | 0.01% | 224 |
|
|
2018
Q3 | $9K | Sell |
140
-660
| -83% | -$39.2K | ﹤0.01% | 240 |
|
|
2018
Q2 | $44K | Buy |
800
+300
| +60% | +$16.2K | 0.02% | 205 |
|
|
2018
Q1 | $32K | Buy |
+500
| New | +$32.2K | 0.02% | 175 |
|
Other funds holding BMY
Prime Capital Investment Advisors's BMY Position: Q2 2026 in Review
Prime Capital Investment Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.5% in Q2 2026, selling an estimated $7.41K and leaving 25,774 shares worth $1.49M. The position accounts for 0.01% of the portfolio, ranked #437.
Prime Capital Investment Advisors first reported a position in BMY in Q1 2018 and has held it in 31 quarters since. The position peaked at $4.27M in Q2 2019. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Prime Capital Investment Advisors held 25,774 shares of Bristol-Myers Squibb worth $1.49M as of Q2 2026.
- Prime Capital Investment Advisors sold 129 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.41K.
- Bristol-Myers Squibb made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #437 holding.
- Prime Capital Investment Advisors first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 31 quarters since.
- Prime Capital Investment Advisors's Bristol-Myers Squibb position peaked at $4.27M in Q2 2019.
- 2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.